Jiangsu Province Centers for Disease Control and Prevention

People's Republic of China

Country: People's Republic of China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.jstd.gov.cn/

Clinical Trials

Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients

Phase 4

Conditions: COVID-19
Pulmonary Tuberculosis

Interventions: Biological: Standard dosage inactivated vaccine
Biological: Double dosage inactivated vaccine

First Posted Date: 2021-12-08

Last Posted Date: 2022-08-16

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 240

Registration Number: NCT05148949

Locations: 🇨🇳
Taizhou People's Hospital, Taizhou, Jiangsu, China
🇨🇳
Danyang Center for Disease Control and Prevention, Zhenjiang, Jiangsu, China
🇨🇳
Huai'an No.4 People's Hospital, Huai'an, Jiangsu, China

and more 3 locations

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Phase 4

Conditions: Influenza

Interventions: Biological: Quadrivalent influenza vaccine

First Posted Date: 2021-12-03

Last Posted Date: 2022-03-31

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 240

Registration Number: NCT05144464

Locations: 🇨🇳
Pizhou City Center for Disease Control and Prevention, Xuzhou, Jiangsu, China

Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine

Phase 1

Completed

Conditions: COVID-19

Interventions: Biological: High dose aerosolized Ad5-nCoV
Biological: inactive SARS-CoV-2 vaccine (Vero cell)
Biological: Low dose aerosolized Ad5-nCoV

First Posted Date: 2021-09-14

Last Posted Date: 2025-02-21

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 423

Registration Number: NCT05043259

Locations: 🇨🇳
Donghai County Center for Diseases Control and Prevention, Lianyungang, Jiangsu, China

Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults

Phase 4

Completed

Conditions: COVID-19

Interventions: Biological: Recombinant SARS-CoV-2 Ad5 vectored vaccine
Biological: Inactive SARS-CoV-2 vaccine (Vero cell)

First Posted Date: 2021-07-07

Last Posted Date: 2022-08-16

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 300

Registration Number: NCT04952727

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)

Phase 4

Completed

Conditions: COVID-19

Interventions: Biological: Inactive SARS-CoV-2 vaccine (Vero cell)
Biological: Recombinant SARS-CoV-2 Ad5 vectored vaccine

First Posted Date: 2021-05-19

Last Posted Date: 2022-03-31

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 300

Registration Number: NCT04892459

Locations: 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

Phase 4

Completed

Conditions: COVID-19

Interventions: Biological: recombinant Ad5 vectored COVID-19 vaccine
Biological: RBD-based protein subunit vaccine (ZF2001) against COVID-19
Biological: trivalent split influenza vaccine

First Posted Date: 2021-04-06

Last Posted Date: 2022-04-06

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 120

Registration Number: NCT04833101

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

Phase 2

Conditions: COVID-19

Interventions: Biological: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56
Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
Biological: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56
Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
Biological: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56
Biological: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56

First Posted Date: 2021-03-24

Last Posted Date: 2022-03-31

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 480

Registration Number: NCT04813562

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)

Phase 2

Withdrawn

Conditions: COVID-19

Interventions: Biological: Recombinant COVID-19 vaccine (Sf9 cells)
Biological: Placebo

First Posted Date: 2021-01-22

Last Posted Date: 2021-05-25

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Registration Number: NCT04718467

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Biological: High-dose placebo (18-59 years) & Three dose regimen
Biological: Low-dose placebo (60-85 years) & Three dose regimen
Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
Biological: High-dose placebo (60-85 years) & Three dose regimen
Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Biological: High-dose placebo (60-85 years) & Two dose regimen
Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Biological: High-dose placebo (18-59 years) & Two dose regimen
Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
Biological: Low-dose placebo (18-59 years) & Two dose regimen
Biological: Low-dose placebo (18-59 years) & Three dose regimen
Biological: Low-dose placebo (60-85 years) & Two dose regimen

First Posted Date: 2020-11-23

Last Posted Date: 2022-06-01

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 960

Registration Number: NCT04640402

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)

Phase 1

Conditions: COVID-19

Interventions: Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Biological: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#
Biological: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Biological: Two doses of placebo at the schedule of day 0, 14 #High-dose group#
Biological: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#
Biological: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14

First Posted Date: 2020-11-19

Last Posted Date: 2022-03-31

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 216

Registration Number: NCT04636333

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Home Terms & Conditions Privacy Policy